Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The combination of XAGE-1 expression and tertiary lymphoid structures predicts prognosis in cutaneous angiosarcoma (Targeted RNA-Seq)

ABSTRACT: To investigate tumor immune microenvironment in cutaneous angiosarcoma, we performed comprehensive RNA sequencing using Next-generation sequencer

ORGANISM(S): Homo sapiens

PROVIDER: GSE203215 | GEO | 2022/12/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

The combination of XAGE-1 expression and tertiary lymphoid structures predicts prognosis in cutaneous angiosarcoma (Targeted RNA-Seq)

Project description:The combination of XAGE-1 expression and tertiary lymphoid structures predicts prognosis in cutaneous angiosarcoma (Targeted RNA-Seq)

| PRJNA839061 | ENA

Angiosarcoma gene expression

Project description:A comparison of gene expression in OCT frozen human angiosarcoma compared with OCT frozen normal mesenchymal tissues

2013-10-21 | GSE44115 | GEO

Chemo-senolytic therapeutic potential against angiosarcoma

Project description:Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.

2024-03-23 | GSE245935 | GEO

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Project description:Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.

| 109483 | ecrin-mdr-crc

Gene expression of human angiosarcoma

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2023-05-03 | GSE226338 | GEO

Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.

Project description: Not available

| S-EPMC7066901 | biostudies-literature

Genome-wide analysis of the effects of propranolol on angiosarcoma tumor cells

2013-06-01 | GSE42534 | GEO

Genome-wide analysis of the effects of propranolol on angiosarcoma tumor cells

Project description:Analysis of the effects of 4 hr and 24 hr propranolol treatment on gene expression of SVR mouse angiosarcoma cells. The hypothesis tested in the present study was that inhibiton of beta adrenergic receptor signaling could ablate the oncogenic properties of angiosarcoma cells. Results provide important information of the response of angiosarcoma cells to ablated beta adrenergic receptor signaling. The total RNA was obtained from mouse angiosarcoma cells cultured in monolayer at 0, 4, and 24 hrs of 50 micromolar propranolol treatment. Illumina microarrays were performed to determine the whole genome expression changes following treatment.

2013-06-01 | E-GEOD-42534 | biostudies-arrayexpress

Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.

Project description: Not available

| S-EPMC5560454 | biostudies-other

miRNA expression profile in angiosarcoma

Project description:We first use microRNA expression profiles to find miRNA expression signatures in 3 cases of human angiosarcoma and capillary hemangiomauman, then RT-PCR for large sample verification. Through the bioinformatics prediction of its target genes, we study its function and aim to find the new molecular markers and therapeutic targets.

2015-02-06 | GSE65657 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data